Doxofylline: A promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 14, 2009, Pages 2343-2356

  Shukla, Dali ^a   Chakraborty, Subhashis ^a   Singh, Sanjay ^a   Mishra, Brahmeshwar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Clinical efficacy; Doxofylline; Low side effects; Safety; Tolerability

Indexed keywords

ALLOPURINOL; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMINOPHYLLINE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL; CIMETIDINE; CLINDAMYCIN; DOXOFYLLINE; EPHEDRINE; ERYTHROMYCIN; ETOFYLLINE; INFLUENZA VACCINE; LINCOMYCIN; PHOSPHODIESTERASE; PROPRANOLOL; QUINOLONE DERIVATIVE; RANITIDINE; SALBUTAMOL; THEOPHYLLINE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE; ZORDOX;

AREA UNDER THE CURVE; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DATA BASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART RATE; HEART RHYTHM; HEARTBURN; HUMAN; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; MEDLINE; NAUSEA AND VOMITING; NERVOUSNESS; NONHUMAN; RECEPTOR AFFINITY; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP PATTERN; STOMACH SECRETION; TACHYCARDIA; TACHYPNEA; TREATMENT INDICATION;

ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DATABASES, BIBLIOGRAPHIC; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE; TREATMENT OUTCOME;

EID: 70349378493     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903200667     Document Type: Review

References (52)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global initiative for chronic obstructive lung disease. Jan 2009. Available from: http://www.goldcopd.com [Last accessed 16 June 2009]
2. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418-424 (Pubitemid 36216426)
3. Mallia P, Contoli M, Caramori G, et al. Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations. Curr Pharm Des 2007;13:73-97 (Pubitemid 46085301)
4. The world health report 1998- life in the 21st century- a vision for all by the world health organization. World Health Organization. March 1998. Available from: http://ftp.who.int/gb/archive/pdf-files/ WHA51/ea3.pdf [Last accessed 16 June 2009]
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997;349:1498-1504
6. Potter BVL. Comprehensive medicinal chemistry. Oxford (UK): Pergamon Press, 1990
7. Manallack DT, Hughes RA, Thompson PE. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem 2005;48:3449-3462
8. Castro A, Jerez MJ, Gil C, Martinez A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 2005;25:229-244 (Pubitemid 40299847)
9. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004;25:430-436 (Pubitemid 38981559)
10. Draheim R, Egerland U, Rundfeldt C. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3, 5-dichloro-pyrid-4-yl)- [1-(4- fluorobenzyl)-5-hydroxy- indole-3-yl]-glycoxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol Exp Ther 2004;308:555-563
11. Jeffery P. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. Pulm Pharmacol Ther 2005;18:9-17 (Pubitemid 39647748)
12. O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004;25:158-163 (Pubitemid 38264507)
13. Spina D. The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy 2004;3:231-236 (Pubitemid 39206651)
14. Mata M, Sarria B, Buenestado A, et al. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-152 (Pubitemid 40222898)
15. Jeon YH, Heo YS, Kim CM, et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 2005;62:1198-1220
16. Houslay MD, Schafer P, Zhang KYJ. Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-1519
17. Dini FL, Cogo R. Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. Curr Med Res Opin 2001;16:258-268 (Pubitemid 32221483)
18. Cruse G, Duffy SM, Brightling CE, Bradding P. Functional KCa 3.1 K+ channels are required for human lung mast cell migration. Thorax 2006;61:880-885
19. Zhou B, Cai SX, Zou F, et al. Effect of doxofylline on calcium-activated potassium channels in human peripheral blood eosinophils in asthma. Zhonghua Jie He He Hu Xi Za Zhi 2005;28:817-819 (Pubitemid 44763489)
20. Sullivan P, Jaffar Z, Page C, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-1008 (Pubitemid 24122609)
21. Franzone JS, Cirillo R, Biffignandi P. Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF. Eur J Pharmacol 1989;165:269-277 (Pubitemid 19181795)
22. Franzone JS, Cirillo R, Barone D. Doxofylline and theophylline are xanthines with partly different mechanisms of action in animals. Drug Explt Clin Res 1988;14:479-489 (Pubitemid 18277545)
23. Franzone JS, Cirillo R, Reboani MC. Doxofylline differs from methylxanthines in its movement of cytosolic calcium. Int J Tissue React 1991;13:131-138
24. Guo H, Xu XY, He LY, Huang JH. Preliminary study on the absorption, distribution and excretion of doxophylline in rats. Yao Xue Xue Bao 1997;32:81-84 (Pubitemid 127463700)
25. Bologna E, Lagana A, Terracino D, et al. Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis. J Int Med Res 1990;18:282-288 (Pubitemid 20243683)
26. Jian G, Chunyan Z, Zhaolong C, et al. The pharmacokinetics of doxofylline in Chinese. Chin J New Drugs 2000;6:396-398
27. Gannu R, Bandari S, Sudke SG, et al. Development and validation of a stability-indicating RP-HPLC method for analysis of doxofylline in human serum. Application of the method to a pharmacokinetic study. Acta Chromatographica 2007;19:149-160
28. Lee JH, Namgung HW, Kwon SY, et al. The pharmacokinetic profiles of oral doxofylline and factors influencing the serum level. Eur Res Cong Abstact Book 2007;Poster-2116: 350s
29. Zhang XR, Chen XY, Hu LD, et al. Evaluation of in-vitro dissolution and in-vivo absorption for two different film-coated pellets of clarithromycin. Arch Pharm Res 2005;28:977-982
30. Huang HF, Lu Y, He HB, Tang X. Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. Drug Dev Ind Pharm 2008;34:676-682 (Pubitemid 351962338)
31. Cipla therapeutic index, respiratory drugs, Zordox. CiplaDoc. Available from: http://www.cipladoc.com/therapeutic/ admin.php?mode=prod&action= disp&id= 650 [Last accessed 16 June 2009]
32. Franzone JS, Cirillo R, Reboani MC. Pharmacological studies in animals of beta-hydroxyethyltheophylline, the major metabolite of doxofylline in humans. Methods Find Exp Clin Pharmacol 1991;13:289-299
33. Bagnato GF. Tolerability of doxofylline in the maintenance therapy of pediatric patients with bronchial asthma. Eur Rev Med Pharmacol Sci 1999;3:255-260 (Pubitemid 32154180)
34. Dolcetti A, Osella D, De Filippis G, et al. Comparison of intravenously administered doxofylline and placebo for the treatment of severe acute airways obstruction. J Int Med Res 1988;16:264-269 (Pubitemid 18212378)
35. Goldstein MF, Chervinsky P. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma - a double-blind randomized placebo-controlled multicentre clinical trial. Med Sci Monit 2002;8:CR297-304 (Pubitemid 34453433)
36. Melillo G, Balzano G, Jodice F, et al. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial. Int J Clin Pharm Res 1989;9:397-405 (Pubitemid 20230500)
37. Poggi R, Brandolese R, Bernasconi M, et al. Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure. Chest 1989;96:772-778
38. Cogo R, Castronuovo A. Effects of oral doxofylline on inflammatory changes and altered cell proliferation in chronic obstructive bronchitis. Eur Rev Med Pharmacol Sci 2004;4:15-20 (Pubitemid 32496403)
39. Villani F, De Maria P, Ronchi E, Galimberti M. Oral doxophylline in patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 1997;35:107-111 (Pubitemid 27129615)
40. Cravanzola C, Reboani MC, Grosa G, Franzone JS. Doxofylline in rat brain in relation to locomotor activity. Drug Metab Dispos 1989;17:437-440 (Pubitemid 19206588)
41. Benditt DG, Benson DW, Kreitt J, et al. Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradyarrhythmias. Am J Cardiol 1983;52:1223-1229 (Pubitemid 14243977)
42. Cirillo R, Barone D, Franzone JS. Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors. Arch Int Pharmacodyn 1988;295:221-237 (Pubitemid 18245714)
43. Dini FL. Chronotropic and arrhythmogenic effects of two methylxanthine bronchodilators, doxofylline and theophylline, evaluated by Holter monitoring. Curr Ther Res 1991;49:978-984
44. Cipri A, Pozzar F, Dini FL. Heart rhythm changes in patients with chronic obstructive bronchopneumopathies: effects of different methylxanthine drugs. Minerva Cardioangiol 1992;40:31-39
45. Giorgi M, Sestini P, Bracciale PM, et al. Treatment with xanthine derivative, doxofylline, in patients intolerant to theophylline. Eur Respir J 1993;6(Suppl 17): Abstract 417
46. Evoniuk G, Jacobson KA, Shamin MT. á1- and á2-selective adenosine antagonists: in vivo characterization of cardiovascular effects. J Pharmacol Exp Ther 1987;242:882-887 (Pubitemid 17156528)
47. Sacco C, Braghiroli A, Grossi E, Donner CF. The effects of doxofylline versus theophylline on sleep architecture in COPD patients. Monaldi Arch Chest Dis 1995;50:98-103
48. Lazzaroni M, Gross E, Porro GB. The effect of intravenous doxofylline or aminophylline on gastric secretion in duodenal ulcer patients. Aliment Pharmacol Ther 1990;4:643-649
49. Information, side effects and warnings of doxofylline methylxanthines. Medical, drugs, pharmaceuticals and diseases information. Available from: http://www.wordpress.rudramani.com/ information-side-effects-and-warnings- ofdoxofylline- methylxanthines/ [Last accessed 16 June 2009]
50. Bagnato G, Fodale P, Bottari M. Clinical evaluation of doxofylline sachets in a pediatric population. Riv Eur Sci Med Farmacol 1989;11:359-363 (Pubitemid 20121138)
51. Cazzola M, Bettoncelli G, Sessa E, Cricelli C. Primary care of the patient with chronic obstructive pulmonary disease in Italy. Respir Med 2009;103:582-588
52. Piaz VD, Giovannoni MP. Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem 2000;35:463-480